Cevostamab

泽沃斯妥单抗

Report date: 2026/05/02 20:00:18

Base Information

Drug NameCevostamab
Drug Alias NameRG-6160BFCR-4350ARO-7187797
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Fc receptor-like protein 5 inhibitors
TargetsT cell surface glycoprotein CD3Fc receptor-like protein 5
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus NephritisMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[20] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdGenentech IncUniversity Of Pennsylvania +[4] 
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLupus NephritisMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A